Angiogenesis-Related Markers and their Potential Clinical Significance

Henderson I.C. , Garber J.E. , Breitmeyer J.B. Comprehensive management of disseminated breast cancer. Cancer 1990; 66: 1439–48.

Porter-Jordan K. , Lippman M.E. Overview of the biologic markers of breast cancer. Hematology/Oncology Clinics of North America 1994; 8(1): 73–100.

O'Hanlon D.M. , Kerin M.J. , Kent P. , Grimes H. , Maher D. , Given H.F. Tissue polypeptide specific antigen in breast cancer - an initial evaluation. Eur J Surg Oncol 1996; 22: 38–41.

Kerin M.J. , McAnnena O.J. , O'Malley V.P. , Grimes H. , Given H.F. CA15-3: Its relationship to clinical stage and progression to metastatic disease in breast cancer. Br J Surg 1989; 76: 838–9.

O'Hanlon D.M. , Kerin M.J. , Kent P. A prospective evaluation of CA15-3 in stage 1 breast carcinoma. J Am Coll Surg 1995; 180: 210–3.

Robertson J.F.R. , Pearson D. , Price M.R. , Selby C. , Blamey R.W. , Howell A. Objective measurement of therapeutic response in breast cancer using serum markers. Br J Cancer 1991; 64: 757–63.

Robertson J.F.R. A prospective confirmation of a biochemical index for measuring therapeutic efficacy in metastatic breast cancer in a metastatic study. The Breast 1996; 5: 372–3.

Gion M. , Barioli P. , Mione R. Tumour markers in breast cancer follow-up: a potentially useful parameter still awaiting definitive assessment (FONCaM). Ann Oncol 1995; 6(Suppl) 1: 31–5.

American Society of Clinical Oncology. Clinical practice guidelines for the use of tumour markers in breast and colorectal cancer. J Clin Oncol 1996; 14: 284–77.

Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1995; 1: 27–31.

Fidler I.J. , Ellis L.M. The implications of angiogenesis for the biology and therapy of cancer metastases. Cell 1994; 79: 185–8.

Martin L. , Green B. , Renshawe C. Examining the technique of angiogenesis assessment in invasive breast cancer. Br J Cancer 1997; 76: 1046–54.

Weinder N. , Folkman J. , Pozza F. Tumour angiogenesis: a new significant and independent prognostic indicator in early stage breast carcinoma. J Natl Cancer Inst 1992; 84: 1850–87.

Horak E. , Leek R. , Klenk N. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 1992; 340: 1120–4.

Heimann R. , Ferguson D. , Powers C. Angiogenesis as a predictor of long-term survival for patients with node negative breast cancer. J Natl Cancer Inst 1996; 88(23): 1764–9.

Van Hoef M. , Knox W.F. , Dhesi S.S. Assessment of tumour vascularity as a prognostic factor in lymph node negative invasive breast cancer. Eur J Cancer 1993; 29A: 1141–5.

Axelesson K. , Ljung B.M. , Moore D.H. Tumour angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Natl Cancer Inst 1995; 87: 997–1008.

Bettleheim R. , Mitchell D. , Gusterson B.A. Immunocyto-chemistry in the identification of vascular invasion in breast cancer. J Clin Pathol 1984; 37: 364–6.

Barbareschi M. , Weidner N. , Gasparini G. Micro-vessel density quantification in breast carcinomas. Assessment by light microscopy vs. a computer-aided image analysis system. Appl Immunohistochem 1995; 3: 75–84.

McNamara D.A. , Harmey J.H. , Walsh T.N. , Redmond H.P. , Bouchier-Hayes D.J. Significance of angiogenesis in cancer therapy. Br J Surg 1998; 85: 1044–55.

Toi M. , Kondo S. , Suzuki H. Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer 1996; 77: 1101–6.

Anan K. , Morisaki T. , Katano M. Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer. Surgery 1996; 119: 333–9.

Yoshiji H. , Gomez D.E. , Shibuya M. , Thorgeirsson U.P. Expression of vascular endothelial growth factor, its receptor and other angiogenic factors in human breast cancer. Cancer Res 1996; 56: 2013–6.

Obermair A. , Kucera E. , Mayerhofer K. Vascular endothelial growth factor (VEGF) in human breast cancer: correlation with disease free survival. Int J Cancer 1997; 74: 455–8.

Relf M. , LeJeune S. , Scott P.A.E. , Fox S. Expression of angiogenic factors vascular endothelial growth factor, acidic and basic fibroblastic growth factor, tumour growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997; 57: 963–9.

Gasparini G. , Toi M. , Gion M. , Verderio P. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997; 89: 139–47.

Kumar H. , Heer K. , Lee P.W.R. Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res 1998; 4: 1279–85.

Heer K. , Kumar H. , Speirs V. , Greenman J. , Drew P.J. , Fox J.N. , Carleton P.J. , Monson J.R.T. , Kerin M.J. Vascular endothelial growth factor in premenopausal women - indicator of the best time for breast cancer surgery? Br J Cancer 1998 (in press).

Scott P.A.E. , Gleadle J.M. , Bicknell R. , Harris A.L. Role of the hypoxia sensing system, acidity and reproductive hormones in the variability of vascular endothelial growth factor induction in human breast carcinoma cell lines. Int J Cancer 1998; 75: 706–12.

Bertin N. , Clezardin P. , Kubiak R. , Frappart L. Thrombospondin-l and −2 messenger RNA in normal, benign, and neoplastic breast tissues: correlation with prognostic factors, tumour angiogenesis, and fibroblastic desmoplasia. Cancer Res 1997; 57: 396–9.

Luqmani Y.A. , Graham M. , Coombes R.C. Expression of basic fibroblastic growth factor, FGFR1 and FGFR2, in normal and malignant human breast, and comparison with other normal tissues. Br J Cancer 1992; 66: 273–80.

Colomer R. , Aparicio J. , Montero S. Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinoma. Br J Cancer 1997; 76(9): 1215–20.

Sliutz G. , Tempfer C. , Obermair A. Serum evaluation of basic FGF in breast cancer patients. Anticancer Res 1995; 15: 2675–8.